Teyi Pharmaceutical Group Co.,Ltd

002728

CNE100001WK6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 27/05/2024 am IST			5-day change	1st Jan Change
9.14 ^CNY	+0.55%		-4.09%	-28.59%

19/04	Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
29/03	Teyi Pharmaceutical Group Co.,Ltd Approves the Cash Dividend for 2023	CI

Teyi Pharmaceutical Group Co.,Ltd Announces Cash Dividend for the Year 2021

March 16, 2022 at 01:02 am IST

Teyi Pharmaceutical Group Co.,Ltd announced cash dividend (tax included) for the year 2021 of CNY 6.50000000 per share.

Latest news about Teyi Pharmaceutical Group Co.,Ltd

Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	19/04	CI
Teyi Pharmaceutical Group Co.,Ltd Approves the Cash Dividend for 2023	29/03	CI
Teyi Pharmaceutical Group Co.,Ltd Proposes Final Cash Dividend for the Year 2023	09/03	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23/23/23	CI
Teyi Pharmaceutical Group Co.,Ltd announced that it has received CNY 274.999916 million in funding from AEGON-Industrial Fund Management Co. Ltd., Donghai Funds Management Co., Ltd., Caitong Fund Management Co., Ltd., Allianz Insurance Asset Management Co., Ltd., Nuode Asset Management Co., Ltd., China Great Wall Securities Co.,Ltd.	28/23/28	CI
Teyi Pharmaceutical's Hypertension Drug Passes Regulatory Evaluation	20/23/20	MT
Teyi Pharmaceutical Group Co.,Ltd(XSEC:002728) added to S&P Global BMI Index	18/23/18	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Teyi Pharmaceutical Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2022, Payable on May 26, 2023	20/23/20	CI
Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for 2022	18/23/18	CI
Teyi Pharmaceutical Group Co.,Ltd Propose Final Cash Dividend for 2022	27/23/27	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Teyi Pharmaceutical Proposes Guangzhou Branch	22/23/22	MT
Teyi Pharmaceutical Ties Up With Educational Institution for Anti-Cough Tablets Study	21/22/21	MT
China stocks end lower as COVID outbreaks cast doubts on reopening	21/22/21	RE
China stocks fall as COVID outbreaks dash hopes of eased curbs	21/22/21	RE
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI
Teyi Pharmaceutical Group Co.,Ltd Announces Management Appointments	29/22/29	CI
Teyi Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 10, 2022	30/22/30	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for the Year 2021	12/22/12	CI
Teyi Pharmaceutical Full-Year Profit Nearly Triples in 2021; Maintains Dividend	16/22/16	MT
Teyi Pharmaceutical Group Co.,Ltd Announces Cash Dividend for the Year 2021	16/22/16	CI

Chart Teyi Pharmaceutical Group Co.,Ltd

Duration

Period

More charts

TEYI PHARMACEUTICAL GROUP CO., LTD, formerly Guangdong Taicheng Pharmaceutical Co., Ltd., is principally engaged in the production and sale of pharmaceuticals. The Company primarily provides Chinese traditional patent medicines, including cough arresting and phlegm removing medicine series, kidney reinforcing medicine series and anti-infection medicine series, among others. The Company's products mainly include tablets, granules, medicinal tea, syrup, decocted extracts, capsules, powder, ointment, cream, as well as oral solutions, among others.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.14

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TEYI PHARMACEUTICAL GROUP CO.,LTD	-28.59%	641M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+31.74%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.44%	205B
ROCHE HOLDING AG	-5.97%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals